A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer

This trial is a Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of QLC5508 in combination with QL2107 versus Tislelizumab plus platinum and etoposide as first-line treatment in participants with extensive-stage small cell lung cancer.

Trial Details

NCT ID
NCT07802821
Phase
PHASE3
Sponsor
Qilu Pharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
Small Cell (SCLC) Lung Cancer
Interventions
  • QLC5508
  • QL2107
  • Tislelizumab
  • Carboplatin
  • Cisplatin
  • Etoposide
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Age ≥18 years.
  • Participants with histologically or cytologically confirmed Extensive-Stage Small Cell Lung Cancer (ES-SCLC) per the Veterans Administration Lung C…
  • No prior systemic treatment for ES-SCLC.
  • At least one extracranial measurable lesion according to RECIST v1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Small Cell (SCLC) Lung Cancer Trials on Trialify →